ViaCyte Company

ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.
Technology: Regenerative Medicine
Industry: Biotechnology, Diabetes, Health Care, Medical, Therapeutics
Headquarters: San Diego, California, United States
Founded Date: 1999-01-01
Employees Number: 51-100
Investors Number: 17
Total Funding: $235.5M
Estimated Revenue: $10M to $50M
Last Funding Type: Venture - Series Unknown

Visit Website
info@ViaCyte.com
https://www.twitter.com/viacyte
Register and Claim Ownership